<DOC>
	<DOCNO>NCT02257645</DOCNO>
	<brief_summary>A multicenter , observational study evaluate safety Euforvac-Hib vaccine active primary immunization diphtheria , tetanus , pertussis , hepatitis B Haemophilus influenza type B infant .</brief_summary>
	<brief_title>Post-authorization Safety Study Euforvac-Hib Vaccine Active Primary Immunization Infants From 6 Weeks</brief_title>
	<detailed_description>Euforvac-Hib vaccine manufacture LG Life science Korea , 's market Korea . It distribute UN agency diverse country . Thus , WHO recommend LG Life Science conduct safety study assess vaccine safety Euforvac-Hib prequalified . The objective safety study identify problem questionable issue likely emerge actual use Euforvac-Hib vaccine launch market .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Patients sign informed consent subject legally acceptable Representative 2 . Infant 6 week age.who give vaccine active primary immunization diphtheria , tetanus , pertussis , hepatitis B Haemophilus influenza type B 1 . Patients hypersensitivity component vaccine 2 . Patients severe reaction previous dose combination vaccine constituent absolute contraindication subsequent dose combination vaccine . 3 . Patients pertussis , encephalopathy serious neurological abnormality newborn period</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>